Editorial: Turning Point towards Blood Biomarker-Guided Targeted Therapy for Precision Medicine in Alzheimer's disease.
作者信息
Hampel H, Vergallo A, Bonuccelli U, Lista S
机构信息
Harald Hampel, MD, PhD, MA, MSc, AXA Research Fund and Sorbonne University Chair, Sorbonne University, Department of Neurology, Institute of Memory and Alzheimer's Disease (IM2A), Brain and Spine Institute (ICM), François Lhermitte Building, Pitié-Salpêtrière Hospital, 47 Boulevard de l'hôpital, 75651 Paris CEDEX 13, France, Phone : +33 1 42 16 75 15, Fax: +33 1 42 16 75 16, E-Mail:
出版信息
J Prev Alzheimers Dis. 2018;5(3):160-164. doi: 10.14283/jpad.2018.25.
Abstract
摘要
相似文献
1
Editorial: Turning Point towards Blood Biomarker-Guided Targeted Therapy for Precision Medicine in Alzheimer's disease.社论：阿尔茨海默病精准医学中迈向血液生物标志物导向的靶向治疗的转折点。
J Prev Alzheimers Dis. 2018;5(3):160-164. doi: 10.14283/jpad.2018.25.
2
Precision Medicine for Preventing Alzheimer's Disease: Analysis of the ADAPT Study.预防阿尔茨海默病的精准医学：ADAPT研究分析
J Alzheimers Dis. 2023;95(4):1609-1622. doi: 10.3233/JAD-230317.
3
Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic.阿尔茨海默病的基于血液的生物标志物：为走向临床铺平道路。
Nat Rev Neurol. 2018 Nov;14(11):639-652. doi: 10.1038/s41582-018-0079-7.
4
CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.脑脊液和血液生物标志物在阿尔茨海默病诊断中的应用：系统评价和荟萃分析。
Lancet Neurol. 2016 Jun;15(7):673-684. doi: 10.1016/S1474-4422(16)00070-3. Epub 2016 Apr 8.
5
Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease
.用于阿尔茨海默病下一代临床试验的基于血液的系统生物学生物标志物
Dialogues Clin Neurosci. 2019;21(2):177-191. doi: 10.31887/DCNS.2019.21.2/hhampel.
6
Editorial: Plasma Biomarker for Alzheimer's Disease: Are We Ready Now for Clinical Practice and Drug Trials?社论：阿尔茨海默病的血浆生物标志物：我们现在是否已准备好用于临床实践和药物试验？
J Prev Alzheimers Dis. 2018;5(3):158-159. doi: 10.14283/jpad.2018.24.
7
A Precision Medicine Initiative for Alzheimer's disease: the road ahead to biomarker-guided integrative disease modeling.阿尔茨海默病精准医学计划：迈向生物标志物引导的综合疾病建模的未来之路。
Climacteric. 2017 Apr;20(2):107-118. doi: 10.1080/13697137.2017.1287866. Epub 2017 Feb 9.
8
A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease.迈向阿尔茨海默病神经炎症机制精准医学之路。
Front Immunol. 2020 Mar 31;11:456. doi: 10.3389/fimmu.2020.00456. eCollection 2020.
9
The Alzheimer Precision Medicine Initiative.阿尔茨海默病精准医学倡议。
J Alzheimers Dis. 2019;68(1):1-24. doi: 10.3233/JAD-181121.
10
The AlzMatch Pilot Study - Feasibility of Remote Blood Collection of Plasma Biomarkers for Preclinical Alzheimer's Disease Trials.阿尔茨海默病匹配先导研究 - 远程采集用于临床前阿尔茨海默病试验的血浆生物标志物的可行性。
J Prev Alzheimers Dis. 2024;11(5):1435-1444. doi: 10.14283/jpad.2024.101.
引用本文的文献
1
Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease
.用于阿尔茨海默病下一代临床试验的基于血液的系统生物学生物标志物
Dialogues Clin Neurosci. 2019;21(2):177-191. doi: 10.31887/DCNS.2019.21.2/hhampel.
本文引用的文献
1
Biomarker and Clinical Trial Design Support for Disease-Modifying Therapies: Report of a Survey of the EU/US: Alzheimer's Disease Task Force.疾病修饰疗法的生物标志物和临床试验设计支持：对欧盟/美国：阿尔茨海默病工作组调查的报告。
J Prev Alzheimers Dis. 2018;5(2):103-109. doi: 10.14283/jpad.2018.13.
2
Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology.阿尔茨海默病精准神经医学的革命。系统生物学和神经生理学的通道。
J Alzheimers Dis. 2018;64(s1):S47-S105. doi: 10.3233/JAD-179932.
3
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.拉罗替尼在成人和儿童TRK融合阳性癌症中的疗效。
N Engl J Med. 2018 Feb 22;378(8):731-739. doi: 10.1056/NEJMoa1714448.
4
Precision pharmacology for Alzheimer's disease.阿尔茨海默病的精准药理学。
Pharmacol Res. 2018 Apr;130:331-365. doi: 10.1016/j.phrs.2018.02.014. Epub 2018 Feb 16.
5
PRECISION MEDICINE - The Golden Gate for Detection, Treatment and Prevention of Alzheimer's Disease.精准医学——检测、治疗和预防阿尔茨海默病的黄金大门。
J Prev Alzheimers Dis. 2016 Dec;3(4):243-259. doi: 10.14283/jpad.2016.112. Epub 2016 Sep 6.
6
A Precision Medicine Initiative for Alzheimer's disease: the road ahead to biomarker-guided integrative disease modeling.阿尔茨海默病精准医学计划：迈向生物标志物引导的综合疾病建模的未来之路。
Climacteric. 2017 Apr;20(2):107-118. doi: 10.1080/13697137.2017.1287866. Epub 2017 Feb 9.
7
Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic.阿尔茨海默病的血液生物标志物：科学现状及从发现到临床推进的新型合作模式。
Alzheimers Dement. 2017 Jan;13(1):45-58. doi: 10.1016/j.jalz.2016.09.014. Epub 2016 Nov 18.
8
A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease.对针对阿尔茨海默病淀粉样蛋白假说的药物发现及3期临床项目的批判。
Ann Neurol. 2014 Aug;76(2):185-205. doi: 10.1002/ana.24188. Epub 2014 Jul 2.
9
Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.设计阿尔茨海默病药物临床试验：从 III 期抗体试验结果发布中得到的经验教训：来自欧盟/美国/CTAD 工作组的报告。
Alzheimers Dement. 2013 Jul;9(4):438-44. doi: 10.1016/j.jalz.2013.03.007.
10
Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease.迈向阿尔茨海默病淀粉样蛋白靶向治疗的早期临床试验。
Nat Rev Drug Discov. 2013 Apr;12(4):324. doi: 10.1038/nrd3842-c1. Epub 2013 Mar 15.
Zotero 插件